Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
FCMR / FAIM3 Antibody (C-Terminus)
Rabbit Polyclonal Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application 
| WB, IHC-P |
|---|---|
| Primary Accession | O60667 |
| Reactivity | Human |
| Host | Rabbit |
| Clonality | Polyclonal |
| Calculated MW | 43kDa |
| Dilution | IHC-P (5 µg/ml), WB (1 µg/ml), |
| Gene ID | 9214 |
|---|---|
| Other Names | Fas apoptotic inhibitory molecule 3, Regulator of Fas-induced apoptosis Toso, FAIM3, TOSO |
| Target/Specificity | 13 amino acid peptide from near the carboxy terminus of human Toso |
| Reconstitution & Storage | Short term 4°C, long term aliquot and store at -20°C, avoid freeze thaw cycles. Store undiluted. |
| Precautions | FCMR / FAIM3 Antibody (C-Terminus) is for research use only and not for use in diagnostic or therapeutic procedures. |
| Name | FCMR {ECO:0000303|PubMed:25888699, ECO:0000312|HGNC:HGNC:14315} |
|---|---|
| Function | High-affinity Fc receptor for immunoglobulin M (IgM), both secreted and membrane-bound IgM (PubMed:19858324, PubMed:22675200, PubMed:36949194, PubMed:37095205). Primarily regulates IgM transport and homeostasis. Primarily regulates IgM transport and homeostasis. In lymphoid cells, enables exocytosis of membrane-bound IgM on the plasma membrane as well as endocytosis of IgM-antigen complexes toward lysosomes for degradation. In mucosal epithelium, mediates retrotranscytosis of antigen-IgM complexes across mucosal M cells toward antigen-presenting cells in mucosal lymphoid tissues (PubMed:21908732, PubMed:28230186). Triggers costimulatory signaling and mediates most of IgM effector functions involved in B cell development and primary immune response to infection. Likely limits tonic IgM BCR signaling to self-antigens for proper negative selection of autoreactive B cells in the bone marrow and for the maintenance of regulatory B cell pool in peripheral lymphoid organs. Mediates antibody responses to T cell-dependent and T cell-independent antigens and promotes induction of an efficient neutralizing IgG response. Engages in cross-talk with antigen-receptor signaling via the non-canonical NF- kappa-B, MAP kinases and calcium signaling pathways (PubMed:19858324, PubMed:22675200, PubMed:25601920, PubMed:30840890). |
| Cellular Location | Cell membrane; Single-pass membrane protein. Early endosome membrane; Single-pass membrane protein. Golgi apparatus, trans- Golgi network membrane; Single-pass membrane protein. Lysosome membrane; Single-pass membrane protein. Note=Continuously recycles between cytoplasmic pool and the plasma membrane to bind as much IgM as possible |
| Tissue Location | Expressed by CD19-positive B cells and CD4-positive and CD8-positive T cell populations in primary and secondary lymphoid tissues (at protein level). Among B cell subsets, detected in a subset of bone marrow pro- and pre-B cells, in most follicular and memory B cells and in a small subset of germinal center B cells (at protein level). Expressed at lower levels in CD56-positive NK cells (at protein level) (PubMed:19858324, PubMed:21908732, PubMed:22675200, PubMed:30840890). Expressed in lymph nodes, lung, thymus and kidneys Very weak expression detected in spleen, liver, heart, and salivary gland. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
May play a role in the immune system processes. Protects cells from FAS-, TNF alpha- and FADD-induced apoptosis without increasing expression of the inhibitors of apoptosis BCL2 and BCLXL. Seems to activate an inhibitory pathway that prevents CASP8 activation following FAS stimulation, rather than blocking apoptotic signals downstream. May inhibit FAS-induced apoptosis by preventing CASP8 processing through CFLAR up-regulation.
References
Hitoshi Y.,et al.Immunity 8:461-471(1998).
Li F.J.,et al.Blood 118:4902-4909(2011).
Kalnine N.,et al.Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
Ota T.,et al.Nat. Genet. 36:40-45(2004).
Gregory S.G.,et al.Nature 441:315-321(2006).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Shipping Information
